Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Pharma Biota Fortunes Rise On Relenza As Swine Flu Drug

This article was originally published in PharmAsia News

Executive Summary

Australia's Biota Holdings stands to be a big winner as most of the world takes steps to block a possible pandemic of swine flu, which has two main treatments, one of them Biota's Relenza (zanamivir). Similarly, sales of Tamiflu (oseltamivir) already are rising For Roche and its inventor, U.S.-based Gilead. Biota developed the Relenza anti-viral, which it manufactures in Australia and licenses to GlaxoSmithKline of the United Kingdom. Both drugs have been shown to be effective against the fast-spreading swine flu the World Health Organization warns could develop into a global pandemic. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts